NT101-AMD-001 (Age-Related Macular Degeneration) - Clinical Trial

¿Cuál es el Propósito de este estudio?

We are doing this study to find out if an experimental drug called NT-101 (the study drug) is a safe and effective option for people with wet age-related macular degeneration (AMD). The study drug is a topical solution that is administered directly to the eye (eye drops).

¿Cuál es la Condición que se está estudiando?

Wet Age-Related Macular Degeneration (AMD)

¿Quién puede participar en el Estudio?

Adults ages 50+ who:

Are diagnosed with wet AMD
Do not have diabetes
Do not have high blood pressure that is not controlled with medication

For more information about this study, contact the study team at DEC-RA@duke.edu.

Grupo etario

Adultos

¿Qué Implica?

If you choose to join the study, you will get a random assignment (like a coin flip) to 1 of 2 groups:

You will either get a 0.05 mM dose of the study drug; OR
You will get a 0.2 mM dose of the study drug

You will take the study drug twice each day for a period of 4 weeks.

Overall, participation in the study will last for about 8 weeks and will involve approximately 6 visits to the study clinic for exams and testing.

Detalles del Estudio

Título Completo

A Randomized, Open-Label, Parallel-group, Multicenter Phase 1/2 Study to Evaluate the Safety and Exploratory Efficacy of NT-101 Topical Ophthalmic Solution in Patients with Wet Age-Related Macular Degeneration (AMD) - NT101-AMD-001

Investigador Principal